Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 1

Метаболические и гемодинамические эффекты нового ингибитора натрий-глюкозного котранспортера 2-го типа ипраглифлозина при лечении сахарного диабета 2-го типа
Т.Ю. Демидова, Я.Г. Алексеева

References

1. International Diabetes Federation. IDF diabetes atlas 2017. Eighth edition. Available from: http://www.diabetesatlas.org/component/attachments/?task=download&id=254 Accessed 2020 Jul 21.
2. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus 2018;21(3):144-59 (In Russian).
3. Dedov II, Omelyanovsky VV, Shestakova MV, Avksentyeva MV, Ignatyeva VI. Diabetes mellitus as an economic problem in the Russian Federation. Diabetes Mellitus 2016;19(1): 30-43 (In Russian).
4. Calderón-Larrañaga A, Abad-Díeza GM, Gimeno-Feliu LA, Marta-Moreno J, González-Rubio F, Clerencia-Sierra M, Poblador-Plou B, Poncel-Falcó A, Prados-Torres A. Global health care use by patients with type-2 diabetes: does the type of comorbidity matter? European Journal of Internal Medicine 2015 Apr;26(3):203-10.
5. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, Marwijk HV, Peek N, Perera-Salazar RP, Reeves D, Rutter MK, Weng SF, Qureshi N, Mamas MA, Kontopantelis E. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Medicine 2019 Jul;17(1):145.
6. Ministry of Healthcare of the Russian Federation; Russian Association of Endocrinologists; National Medical Research Center for Endocrinology. Standards of specialized diabetes care. Clinical guidance. Dedov II, Shestakova MV, Mayorov AYu, editors. 9th ed., revised. Diabetes Mellitus 2019;22(S1):1-144. (In Russian).
7. Lim S, Eckel RH, Koh KK. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis 2018 May;272:33-40.
8. Cosentino F, Grant PJ, Aboyans V, Bailey GJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020 Jan;41(2):255-323.
9. American Diabetes Association. Standards of medical care in diabetes – 2019. Diabetes Care 2018;42(Suppl 1):S1-S194.
10. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 2017 Jul;136(3):249-59.
11. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. Journal of the American College of Cardiology 2018 Jun;71(23):2628-39.
12. Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Advances in Therapy 2019 Oct;36(10):2567-86.
13. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015 Jan;75(1):33-59.
14. Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Therapy 2019 Oct;10(5):1771-92.
15. Chilton RJ. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes, Obesity & Metabolism 2020 Jan;22(1):16-29.
16. Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, Klasen S. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2013 May-Jun;27(3):268-73.
17. Kashiwagi A, Kazuta K, Takinamiet Yu, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetology International 2015 Mar;6(1):8-18.
18. Elgebaly A, Abdelazeim N, Abdelazeim B, El Ashal G, Mattar O, Namous L, Nasreldin N. Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis. Experimental and Clinical Endocrinology & Diabetes 2018 Jun 18. doi: 10.1055/a-0579-7860. Online ahead of print.
19. Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes, Obesity & Metabolism 2015 Mar;17(3):304-8.
20. Kashiwagi A, Akiyama N, Shiga T, Kazuto K, Utsuno A, Yoshida S, Ueyama E. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetology International 2015;6(2):125-38.
21. Kashiwagi A, Shiga T, Akiyama N, Kazuta K, Utsuno A, Yoshida S, Ueyama E. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetology International 2015;6(2):104-6.
22. Kashiwagi A, Isaka H, Kawano H, Kazuta K, Utsuno A, Yoshida S. Long-term safety, tolerability and efficacy of ipragliflozin in combination with a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus inadequately controlled with a dipeptidyl peptidase-4 inhibitor alone – DAYLIGHT study. Japanese Pharmacology & Therapeutics 2014;42(12):941-57.
23. Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. Journal of Diabetes Investigation 2016 May;7(3):366-73.
24. Han KA, Chon S, Chung CH, Lim S, Lee KW, Baik SH, Jung CH, Kim DS, Park KS, Yoon KH, Lee IK, Cha BS, Sakatani T, Park S, Lee MK. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial. Diabetes, Obesity & Metabolism 2018 Oct;20(10):2408-15.
25. Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes, Obesity & Metabolism 2016 Dec;18(12):1207-16.
26. Ishihara H, Yamaguchi S, Nakao I, Sakatani T. Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): a 52-week open-label study. Diabetes Therapy 2018 Aug;9(4):1549-67.
27. Shestakova MV, Wilding JPH, Wilpshaar W, Tretter R, Orlova VL, Verbovoy AF. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2018 Dec;146:240-50.
28. Cowie СС. Diabetes diagnosis and control: missed opportunities to improve health: the 2018 Kelly West Award lecture. Diabetes Care 2019 Jun;42(6):994-1004.
29. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 2017 Feb;24(1):73-9.
30. Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opinion on Pharmacotherapy 2018 Feb;19(3):189-201.
31. Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. Journal of Clinical and Medicine Research 2017 Jul;9(7):586-95.
32. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V Study Group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes, Obesity & Metabolism 2019 Aug;21(8):1990-5.
33. Tahara A, Kondo Y, Takasu T, Tomiyama H. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. Biomedicine & Pharmacotherapy 2018 Sep;105:1033-41.
34. Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M, Shimada A. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017 Oct;40(10):1364-72.
35. Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clinical Drug Investigation 2016 Apr;36(4):313-9.
36. Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, a placebo-controlled clinical trials. Diabetology International 2017 Mar;8(1):76-86.
37. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Current Diabetes Reports 2008;8(1):71-7.
38. Russian National Atherosclerosis Society (RNAS); Russian Society of Cardiology (RSC); Russian Diabetic Association (RDA). Diagnostics and correction of lipid metabolism disorders to prevent and treat atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and Dyslipidemia 2020;1(38):7-42 (In Russian).
39. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes & Vascular Disease Research 2015;12(2):90-100.
40. Kashiwagi A, Sakatani T, Nakamura I, Akiyama N, Kazuta K, Ueyama E, Takahashi H, Kosakai Y. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. Endocrine Journal 2018 Jul;65(7):693-705.
41. Bando Y, Tohyama H, Aoki K, Kanehara H, Hisada A, Okafuji K, Toya D. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. Journal of Clinical and Translational Endocrinology 2016 Dec;6:1-7.
42. Lo KВ, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Medicine 2020;10(1):1-10.
43. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 2019 Jan;393(10166):31-9.
44. Rådholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW, Perkovic V, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – a systematic review. Diabetes Research and Clinical Practice 2018 Jun;140:118-28.
45. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Current Diabetes Reports 2018;18(5):27.
46. Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: an analysis from a multicenter prospective intervention study. Journal of Diabetes Investigation 2020 Mar 9. https://doi.org/10.1111/jdi.13248. Online head of print.
47. Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018 Nov;363:k4365.
48. Donnan JR, Grandy CA, Chibrikov E, Marra SA, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 2019;9(1):e022577.
49. Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. The Lancet. Diabetes & Endocrinology 2017 Sep;5(9):680-1.
50. Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang P, Berlin JA, Rosenthal N. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes, Obesity & Metabolism 2018 Nov;20(11):2585-97.
51. Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH. Safety of ipragliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase II/III/IV clinical trials. Diabetes Therapy 2019 Dec;10(6):2201-17.
52. Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opinion in Pharmacotherapy 2016 Jul;17(15):1995-2003.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]